Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacille Calmette-Guerin vaccine
- Development stage
- Approved
- Lead developer
- Sant'Andrea Hospital
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Bacille Calmette-Guérin (BCG) vaccine is a live attenuated strain of *Mycobacterium bovis* traditionally used for tuberculosis prevention. In a clinical program led by S. Andrea Hospital, it is being repurposed as an immunomodulatory therapy for radiologically isolated syndrome (RIS), a preclinical stage of multiple sclerosis. The vaccine is administered as a single intradermal injection and is hypothesized to prevent neuroinflammation and the progression of demyelinating lesions by inducing tumor necrosis factor (TNF) and modulating systemic immune responses. This approach aims to provide a safe, cost-effective, and accessible secondary prevention strategy for individuals at high risk of developing clinical multiple sclerosis.
- Brand names
- TICE BCGOncoTICEImmucystBCG Vaccine
- Other names
- BCGBacillus Calmette-GuerinBCG vaccineBCG Moreau
02
Targets
αMβ2 (Integrin αMβ2)TLR4 (Toll-like receptor 4)CLEC4E (Macrophage-inducible C-type lectin receptor)DC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin)TLR2 (Toll-like Receptor 2)MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on bacille Calmette-Guerin vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacille Calmette-Guerin vaccine.